Clinical Trial

Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety.

Study acronym: MDR
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Objective of this study is to compare the efficacy and safety between combination of colistin and meropenem and combination of amikacin and meropenem for multi-drug-resistant gram-negative bacteria in Intensive Care Unit. In Beni- Suef University Hospital.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-08-30 2026-07-15
minor Completion pushed: 2026-06-30 -> 2026-09-30 2026-07-15
Trial Details
NCT Number NCT07694700
Lead Sponsor Beni-Suef University
Conditions MDR Bacteria
Enrollment 100 participants
Start Date 2025-12-30
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14